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Summary: Significant progress has been made in the characterization of cartilage and bone differentiating
proteins. A family of unique proteins known as bone morphogenetic proteins has been described, and there is
ample evidence that they are directly responsible for de novo cartilage and bone formation in vivo. Extensive
research is underway to develop appropriate and optimal delivery systems based on extracellular matrix
components. It is likely that bone morphogenetic proteins will play a crucial role in bone and joint regeneration
and repair.
Epithelial and Bone Matrix Induced Osteogenesis Demineralized Bone Matrix-Induced Osteogenesis
The bone has a remarkable potential for repair and re-
generation. Regeneration processes such as fracture re-
pair, recapitulate events that occur in the course of em-
bryonic bone development. Experimental means of in-
ducing new bone formation at non-bony sites have been
known for years. In early 1930, Huggins (1) discovered
that surgical transplantation of living urinary bladder ep-
ithelium into abdominal muscles in dogs resulted in new
bone formation. The phenomenon was termed "epithe-
lial Osteogenesis". Urist (2) and Reddi & Huggins (3)
have shown that implantation of demineralized bone
matrix into intramuscular or subcutaneous sites induced
a sequence of cellular events leading to the formation of
cartilage, bone, and bone marrow. The events were
termed "matrix-induced endochondral bone formation".
Inductive properties of demineralized bone matrix im-
plantation at heterotopic sites are also reminiscent of
embryonic bone development. It is believed that the
putative molecules responsible for epithelial and mat-
rix-induced Osteogenesis may have common structural
properties, although this has not yet been demon-
strated.
The cascade of matrix-induced endochondral bone for-
mation consists of chemotaxis, attachment of mesenchy-
mal stem cells to the matrix, proliferation of progenitor
cells, and differentiation of cartilage (fig. 1). This is fol-
lowed by cartilage resorption, bone formation, and fi-
nally culminating in the formation of an ossicle filled
with haematopoietic marrow (4). On day 1, fibronectin
is deposited on the matrix facilitating cell attachment.
On days 2 and 3, proliferation of mesenchymal cells
takes place. This cell-matrix interaction results in the
differentiation of chondroblasts at day 5, with appear-
ance of cartilaginous matrix as shown by an increased
35S (sulfate) incorporation into proteoglycans, and the
appearance of hypertrophic chondrocytes at day 7. Angi-
ogenesis with cartilage resorption starts on day 9, and
new bone formation in association with 45Ca incorpora-
tion into new bone mineral occurs at day 11 (fig. 1).
Extensive bone remodeling with haematopoietic marrow
formation, as evidenced by 59Fe incorporation, is maxi-
mal on day 21. This development programme is a single
cycle of cartilage and bone formation, and recapitulates
the embryonic development of limbs (fig. 1). It could be
Bur J Clin Chem Clin Biochem 1995; 33 (No 10)





Fig. 1 Induction of endochondral bone formation cascade after
subcutaneous implantation of demineralized bone matrix. 35S indi-
cates incorporation of sulfate into proteoglycans during chondro-
genesis. Phosphatase stands for alkaline phosphatase in indicating
osteogenesis. 45Ca reflects mineralization of bone matrix, and 59Fe
measures haematopoiesis.
a useful model for fracture healing. Moreover, this sys-
tem enables molecular studies at the different stages of
endochondral bone formation and a better understanding
of the role of endogenous and exogenous growth and
differentiation factors involved.
The Discovery of Osteogenin and
other Bone Morphogenic Proteins
Identification of osteogenic proteins in mammalian bone
matrix responsible for this cascade of cartilage and bone
differentiation has been a difficult task due to the low
abundance of osteogenin and related bone morphogene-
tic proteins tightly bound to the bone extracellular ma-
trix. Progress in recent years in the study of bone mor-
phogenetic proteins has been aided by four important
technical developments, namely:
1. the development of a functional bioassay in a subcuta-
neous site in a rat to monitor the specific biology of
osteogenic activity (5, 6);
2. the development of a specific purification procedure
involving heparin affinity chromatography (7);
3. the use of electroendosmotic elution techniques after
preparative sodium dodecyl sulfate gel electrophoresis
to achieve final purification homogeneity (8); and
4. the use of recombinant DNA methodologies for the
cloning and expression of several members of the bone
morphogenetic proteins family (9-12).
A breakthrough in the isolation of osteogenic activity has
been the dissociative extraction of demineralized bone
matrix by 4 mol/1 guanidinium hydrochloride, or 8 mol/1
urea (5). Neither the soluble extract nor the residual bone
powder alone had detectable activity when implanted sub-
cutaneously in a rat. However, when the extract was re-
constituted with the inactive residue, biological activity of
bone and cartilage formation was recovered (fig. 2). This
reconstitution assay has permitted the further purification
of osteogenic components. Additional experiments re-
vealed that irrespective of the species, the lower molecu-
lar weight fractions of a 4 mol/1 guamdiniuin hydrochlo-
ride extract following molecular sieve chromatography
induced new cartilage and bone formation in rats (5). This
discovery set the stage for the large scale purification of
bone and cartilage inducing proteins.
A group of related bone morphogenetic factors has been
discovered that include osteogenin, bone morphogenetic
protein-2 (BMP-2), BMP-3, BMP-4, BMPs 5 and 6, os-
teogenic protein-1 (BMP-7), and osteogenic protein-2
(BMP-8) (8-11, 13, 14). Osteogenin was purified to
Fig. 2 Photomicrograph of a histological section of an implant
of baboon insoluble collagenous matrix reconstituted with baboon
osteogenin (bone morphogenetic protein-3) and implanted ex-
traskeletally in baboons. Note bone differentiation in direct contact
with the implanted collagenous matrix. Contiguous osteoblasts li-
ning the newly formed bone (toluidine blue; X 125) (Reproduced
from Ripamonti et al.: Matrix 1992; 12:3^69) (44).
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Tab. 1 Family of bone morphogenetic proteins (BMPs) and carti-




























Osteogenin / Bone morphogenetic protein family




Bone morphogenetic protein-2 (BMP-2)
Bone morphogenetic protein-4 (BMP-4)
Bone morphogenelic protein-5 (BMP-5)
Bone morphogenetic protein-6 (BMP-6)
Osteogenic protein-1 (OP-1, BMP-7)




















Bone morphogenetic protein-4 (BMP-4)
Bone morphogenetic protein-2 (ΒΜΡτ2)
Bone morphogenetic protein-5 (BMP-5)
Osteogenic protein-1 (OPrl)
Bone morphogenetic protein-6 (BMP-6)
60A- '-  ττ^
Dccapentaplegic protein (-DPP)— *±-^
Cartilage-derived morphogenetic protcin-1 (CDMP-1)
Cartilage-derived morphojgchetic protein-2 (CDMPrl)
Growth differentiation protein-1 - —- ,:·....
Osteogenin (BMP-3) *—. ^ : - - -
Fig. 3a Members of the transforming growth factor β (TGF- )
superfamily.
DPP = decaperitaplegic protein; MIS = Mullerian inhibiting sub^
stance; VG-1 =?= vegetal pole derived transcripts; BMPs = bone
morphogenetic proteins; CDMPs = cartilage-derived morphogene-
tic proteins. Percentage identity in comparison to bone morphogen-
etic protein-3.
Fig. 3b Identities between 7-cysteine mature portions of the
transforming growth factor- family members.
homogeneity from bovine bone matrix, and the se-
quences of several tryptic peptides were determined (8).
The sequences were similar to portions of the amino
acid sequence deduced from the cDNA clone of bone
morphogenetic protein-3 (9). Osteogenin shows 49 and
48% sequence identity in its carboxyl-terminal quarter
to bone morphpgenetic protein-2 and bone morphogene-
tic protein-4, respectively (9). Bone morphogenetic pro-
tein-7 was found to be identical to Osteogenic protein-1
(11, 14). Based on structural and amino acid sequence
homologies, these osteogenic proteins are grouped
among members of the transforming growth factor β su-
perfamily (tab. 1), all of which share a striking homol-
ogy in the C-terminal domain (fig. 3a).
Osteogenin and related bone morphogenetic proteins ini-
tiate cartilage and bone formation in vivo. Bone mor-
phogenetic protein-3 is most abundant in the highly puri-
fied preparations, but other members, especially bone
morphogenetic protein-2 and bone morphogenetic pro-
tein-7 (osteogenic protein-1), are also present in the bio-
active highly purified bone-derived fractions. Bone mor-
phogenetic proteins 2-4 and bone morphogenetic pro-
tein-7 have been reported to induce cartilage and bone
as single recombinant proteins in conjunction with resi-
due (9, 11, 12, 14). The availability of all the recombi-
nant proteins will allow researchers to address the ques-
tion of particular functions of different members in en-
dochondral bone formation more accurately. The studies
of the mechanism of action of the bone morphogenetic
proteins will add considerable new information on the




Fig. 4 mRNA expression of bone morphogenetic protein-3 in fe-
tal human tissues. The sizes of the bone morphogenetic protein-3
mRNA species are shown on the left. Fetal (12—14 weeks) tissues
are indicated above the lanes.
RNA sieve markers are indicated on the right (9.0, 7.5, 4.4, 2.4
and 1.35 · 103 bases). (Enzyme = glyceraldehyde phosphate dehy-
drogenase.) (Reproduced from Vukicevic et al.; J Histochem Cy-
tochem 1994; 7:869).
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molecular signals controlling cartilage and bone forma-
tion, as well as cartilage and bone regeneration.
As in the case of transforming growth factor-ß, members
of transforming growth factor-ß superfamily are synthe-
sized as a large precursor, four times greater than the
mature form of the molecule. Members of this family
encode secreted polypeptides that share common struc-
tural features (fig. 3b). They are proteolytically pro-
cessed from the pro-protein to yield the carboxyl termi-
nal mature proteins of approximately 110 amino acids as
disulphide-linked homodimers. The active ligand form is
a disulphide-bonded homodimer of a single family
member or a heterodimer of two different members
(15-17). All members share a conserved pattern of
seven highly conserved cystein residues.
Involvement of Bone Morphogenetic Proteins
in Development
There is accumulating evidence that morphogenetic pro-
teins are important regulators of many morphogenetic
events during embryogenesis. For example, recent in
situ hybridization studies for bone moiphogenetic pro-
tein-2, bone morphogenetic protein-4 and bone morpho-
genetic protein-6 revealed, in addition to the expected
localization of transcripts in cells involved in skeletal
morphogenesis, mRNA transcripts i'rf several extraskele-
tal organs and tissues, namely: the developing limb, the
myogenic layer of the atrioventricular cushions of the
developing heart, developing hair and whisker follicles,
tooth buds and palate, developing central nervous sys-
tem and craniofacial tissues (18-20). Osteogenic pro-
tein-1 was identified in human placenta and in brain
cDNA libraries (21) and by Northern hybridization
analysis bone morphogenetic protein-3 to 6 mRNAs
have been found in the lung (fig. 4). Bone morphogene-
tic protein-3 message was found by in situ hybridization
in perichondrium, periosteum/osteoblast layer, intestine,
kidney and lung, which is a major site of synthesis dur-
ing development (21, 22).
By using Northern analysis and immunohistochemistry,
osteogenic protein-1 was localized not only in osteo-
Fig. 5 Expression of murine tooth germs. Transcripts are found lium, -(C) Darkfield image with transcripts in the nasal epithelium,
in several craniofacial structures including molar and incisor teeth. odontoblasts and dental papilla of the incisor tooth. (D) Brightfield
(A) Darkfield image of transcripts in the dental epithelium. (B) A image of (C). Arrow points to the ameloblast layer of the incisor
corresponding brightfield section. Arrows indicate dental epithe- tooth. *
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genie sites, but also in kidney, adrenal, urinary bladder,
developing heart and a number of basement membranes
separating the epithelium from the underlying stroma
(11, 13, 23). Osteogenic protein-1 transcripts are present
in a variety of tissues, suggesting local and/or systemic
release, particularly in the development of kidney, limb
bud, bone, tooth (fig. 5), heart and intestine (24).
These data together with the specific affinity of osteoge-
nin and bone morphogenetic protein-2 for the type IV
collagen of the basement membrane (25), underscore the
potential critical role of the extracellular matrix in se-
questering differentiation factors and in regulating their
bioavailability.
Involvement of Bone Morphogenetic Proteins
in the Endochondral Bone Formation Cascade
In vitro studies allowed us to explore the effects of bone
morphogenetic proteins on both cartilage and bone cells.
Osteogenin stimulated alkaline phosphatase activity and
collagen synthesis in rat periosteal cells and calvarial
osteoblasts (26). There was also an increase in the for-
mation of alkaline phosphatase-positive colonies in rat
bone marow stromal cell cultures (26). The promotion of
the osteogenic phenotype was confirmed in experiments
with MC3T3-E1 osteoblastic cells; Osteogenin inhibited
growth and stimulated alkaline phosphatase activity
within 72 hours (27), while usually about 12 days are
needed for their spontaneous differentiation in vitro
(28). In the same cells, high-affinity receptors for bone
morphogenetic protein-2 have been identified (29). Sev-
eral studies using either bone morphogenetic protein-2,
3 or 4 have confirmed and extended these original data
on bone morphogenetic proteins promoting the osteo-
blastic phenotype (30—32).
Chondrogenic act ivi ty of bone morphogenetic
proteins
A profound stimulation of proteoglycan synthesis in fe-
tal rat chondroblasts and rabbit articular chondrocytes
(26), together with increased cartilage matrix synthesis
in chick limb bud cell cultures (33—34), demonstrated
the role of osteogenin in the promotion of the chondro-
genic phenotype. Osteogenin and bone morphogenetic
protein-4 were equipotent in the maintenance of pro-
teoglycan metabolism in articular cartilage explant cul-
tures of young, adolescent and adult tissues by increas-
ing proteoglycan synthesis and decreasing proteoglycan
catabolism (35). Analysis of the newly synthesized pro-
teoglycans, the glycosaminoglycan chain size, and the
glycosaminoglycan type of explants treated with os-
teogenin or bone morphogenetic protein-4 indicated that
they were very similar. Thus, both osteogenin and bone
morphogenetic protein-4 alone are capable of stimulat-
ing and maintaining the chondrocyte phenotype in vitro
(35). Taken together, these in vitro data suggest that
bone morphogenetic proteins play a role not only in the
initiation of cartilage and bone formation, but clearly
promote the expression and maintenance of the chon-
drogenic and osteogenic phenotype. The potential role
Fig. 6 Composite photomicrographs of sagittal sections of three
baboon cranial defects A-C. Full-thickness circular cranial defects,
25 mm in diameter were trephined on the exposed calvariae and
implanted with insoluble cpllagenous matrix reconstituted with ba-
boon osteogenin (bone morphogenetic protein-3). Sections were
cut from three specimens harvested from three different animals
on day 90 after surgery. Extensive bone formation is present in all
adult primates. (Reproduced from Ripamonti et al.; Plast Reconstr
Surg 1993; 91:27) (43).
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of bone mo hogenetic proteins in healing cartilage
defects is described later. It was found that osteogenic
protein-1 (BMP-7) promotes cell proliferation and
chondrocyte maturation without requiring either thy-
roid hormone or insulin, agents known to support
chondrocyte differentiation in vitro. By comparison,
transforming growth factor-ß and retinoic acid neither
initiated nor promoted chondrocyte differentiation (36).
Discovery and Potential Function of Cartilage-
Derived Morphogenetic Proteins
Partially purified extracts from newborn calf articular
cartilage were found to induce cartilage and bone when
implanted subcutaneously in rats. This activity showed
characteristics reminiscent of bone morphogenetic pro-
teins. Degenerated oligonucleotide primer sets derived
from the highly conserved carboxy-terminal region of
the bone morphogenetic protein family were designed
and used in reverse transcription-polymerase chain reac-
tions with poly(A)+ KNA from articular cartilage as
template to determine which bone morphogenetic pro-
teins are produced by chondrocytes. Two novel members
of the transforming growth factor-ß superfamily were
identified and designated as cartilage-derived morpho-
genetic protein-1 and -2. Their C-terminal transforming
growth factor-ß domains are 82% identical, thus defin-
ing a novel subfamily most closely related to bone mor-
phogenetic protein-5, bone morphogenetic protein-6 and
osteogenic protein-1 (fig. 3b). Northern analyses showed
that both genes are expressed predominantly in cartilagi-
nous tissues. In situ hybridization and immunostaining
showed that cartilage-derived morphogenetic protein-1
was found predominantly at the stage of precartilaginous
mesenchymal condensation and throughout the cartilagi-
nous cores of the developing long bones, whereas carti-
lage-derived morphogenetic protein-2 expression was
restricted to the hypertrophic chondrocytes of ossifying
long bone centers (37). Neither gene was detectable in
the axial skeleton during human embryonic develop-
ment. The genetic map location for cartilage-derived
morphogenetic protein-1 was defmefl on mouse chromo-
some 2 by Southern blot analysis of the progeny of two
multilocus crosses. The cartilage-specific localization
pattern of these novel transforming growth factor-ß
superfamily members, which contrasts with the more
ubiquitous presence of other bone morphogenetic pro-
tein family members, suggests a potential role for
these proteins in chondrocyte differentiation and
growth of long bones (37). Moreover, recombinantly
expressed cartilage-derived morphogenetic protein-1
induced cartilage at ectopic sites in rats (tab. 1). Sev-
eral recombinantly expressed bone mqrphogenetic pro-
teins can induce bone at ectopic sites in vivo (tab. 1).
This apparent redundancy has gained much attention
and recently it has been demonstrated that, apart from
inducing bone development and regeneration, different
bone morphogenetic proteins are the key mediators in
initiating the development of parenchymatoüs organs;
e. g. bone morphogenetic protein-4 mediation of tooth
development (38) and osteogenic protein-1 initiation
of kidney mesenchyme induction (Vukicevic et al., in
preparation).
Potential Therapeutic Application of
Bone Differentiation Factors
The availability of bone morphogenetie proteins has
made it possible to extend the knowledge of their in
vivo morphogenic potential in rodents to primates, a
prerequisite for the exploration of potential therapeutic
applications for the regeneration of bone in man.
Tab. 2 Skeletal localization and the type of bone morphogenetic protein preparation used for
craniofacial regeneration
Skeletal localization and species Authors
1. Regeneration of calvaria in dogs (bovine bone morphogenetic protein)
2. Bone morphogenetic protein and ß-tricalcium phosphate composite in skull trephine defects
in dogs (bovine bone morphogenetic protein)
3. Repair of craniotomy defects in rhesus monkey (bovine bone morphogenetic protein)
4. Calvarial reconstruction in baboons (recombinant human bone morphogenetic protein)
5. Mandibular reconstruction in dogs (recombinant human bone morphogenetic protein)
6. Regeneration of attachment apparatus of the human teeth (human bone morphogenetic
protein)
7. Repair of rat craniotomy defects (bovine bone morphogenetic protein)
Sato K, Urist MR. 1985 (39)
UristMRet&L 1987(40)
Ferguson D et al. 1987 (41)
Ripamonti U. 1991 (42),
Ripamonti U et al. 1992 (43)
Toriumi MD et al. 1991 (79)
Bowers G et al. 1991 (80)
Marfyn JL et *\. 1993(44)
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Craniofacial applications
Table 2 shows the skeletal localization and the type of
bone morphogenetic protein preparation used for experi-
ments on the craniofacial skeleton.
First experiments on craniofacial regeneration were car-
ried out using bovine native bone morphogenetic pro-
tein. Bone regeneration under the influence of a bone
morphogenetic protein ß-tricalcium phosphate compos-
ite in skull trephine defects in dogs was investigated by
Uns t et al. (39). ß-Tricalcium phosphate was employed
as a non-immunogenic biodegradable delivery system
for bovine bone morphogenetic protein. Bone morpho-
genetic protein/ß-tricalcium phosphate implants induced
91-100% of new bone deposits (39, 40). Ferguson et
al. (41) proved that purified bovine bone morphogenetic
protein induces repair of craniotomy defects. The mor-
phogenetic responses included mesenchymal cell prolif-
eration, chondrogenesis, and increased bone formation.
The healing potential of osteogenin on calvarial defects
in a series of adult primates of genus Papio (baboon)
has been studied. In 48 adult male baboons, calvarial
defects were implanted with graft of autogenous bone
harvested from the iliac crest, and with different osteo-
conductive and osteoinductive substrates (42). Reconsti-
tution of calvarial defects with baboon osteogenin in-
duced huge amounts of new bone as early as 30 days.
At 3 months, bone formation was extensive, culminating
in complete regeneration of the craniotomy defects
(43—46). A single application of human recombinant
transforming growth factor- 1 in a 3% methylcellulose
gel to skull defects in New Zealand white rabbits in-
duced a dose dependent increase in intramembranous
bone formation (47). Complete bony bridging of defects
occurred within 28 days after treatment with 2 g of
transforming growth factor-ßl. Transforming growth
factor-ßl in contrast is not osteogenic when implanted
with a carrier at orthotopic sites (7, 8, 48).
Bone morphogenetic proteins were recently tested for
their regenerating effects in human periodontal intra-
bony defects (49, 50). Combined with insoluble collage-
nous bone matrix, bone morphogenetic proteins induced
regeneration of cementum, periodontal ligament and al-
veolar bone in furcation defects created in adult baboons
(50). Periodontal regeneration is one of the major goals
of periodontal therapy. The use of recombinant human
bone morphogenetic proteins is in the experimental
phase, but shows promise of increasing the regeneration
of enamel and periodontal ligament and augmentation
of mandibles (49, 50).
Orthopaedic applications
Two preliminary reports on the treatment of large bony
defects in human lower limbs by implants containing
native human bone morphogenetic protein have been
published. In the first, 12 patients with established non-
union of the femoral diaphysis junction received autoge-
nous grafts or allografts with the preparation of purified
bone morphogenetic protein (51). Union was obtained
in 11 of 12 cases at an average time of 4.7 months after
grafting. The second report described 6 patients with
segmental tibial defects, 3 to 17 cm long, who obtained
solid bony union after implantation of bone morphogen-
etic protein and autogenous bone grafts (52). The os-
teogenic effect of bone morphogenetic protein in such
Tab. 3 Experimental and clinical orthopaedic applications of bone morphogenetic proteins
Dkeletal localization and species Authors
1. Grafting of resistant femoral non-unions (purified bone morphogenetic proteins)
2. Cancellous bone grafts augmented with purified bone morphogenetic protein in
repair of segmental defects of the tibia
3. Purified bone morphogenetic protein and insoluble non-collagenous proteins in
extensive (3-4 cm) segmental ulnar defects in dogs
4. Healing of segmental bone defects (in femurs of adult male rats) recombinant
human bone morphogenetic protein-2
5. Healing of large mid-part defects of the ulnar shaft of adult rabbits; recombinant
human osteogenic protein-1
6. Ulnar or tibial diaphyseal segmental defects in rabbits, dogs and primaes;
recombinant human osteogenic protein-1
7. Rats and rabbits osseous defects; recombinant human bone morphogenetic
protein-2
8. Canine and rabbit spinal fusion model (recombinant human bone morphogenetic
protein-2 and recombinant human osteogenic protein-1)
Johnson EE9 Urist MR et al. 1988 (51-52)
Johnson EE, Urist MR et al. 1989 (81)
Johnson EE, Urist MR et al. 1989 (81)
Yasko WA et al. 1992 (53)
CookDS&ti. 1994(54)
Rueger DC, Tucker MM, Cook SD 1994 (55)
Lane JM, Yasko A et al. 1994 (56)
Musher FG et al. 1994 (57), Cook DS et al.
1994 (58), Boden SD et al. 1994 (59),
Sandhy HS et al, 1994 (60), Yasko (53)
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complex procedures was difficult to estimate. Neverthe-
less, the results were encouraging, since most of the pa-
tients had previously undergone several unsuccessful
operations (tab. 3). Recently, several investigations using
bone morphogenetic proteins obtained by recombinant
technology have been concluded confirming positive re-
sults in bone regeneration achieved with native bone
morphogenetic protein preparations. Yasko et al. (52) in-
vestigated the healing of segmental femoral defects in
rats induced by recombinant human bone morphogenetic
protein-2. Two doses (1.4 or 11.0 μ§) of lyophilised re-
combinant human bone morphogenetic protein-2 were
implanted in each defect, together with guanidine-hy-
drochloride extracted demineralized rat-bone matrix as
a carrier. Implantation of 11.0 μg of recombinant human
bone morphogenetic protein-2 resulted in significant
bone formation, as shown by radiographic, histological
and mechanical evidence of union'.f
Cook et al. (54) investigated the effect of recombinant
human osteogenic protein-1 (BMP-7) on healing of large
segmental ulnar defects in rabbits. The implants con-
sisted of a collagen carrier (125 mg) of demineralized
guanidine-extracted, insoluble rabbit bone matrix, recon-
Tab. 4 Various organic and inorganic materials used as bone morphogenetic protein carriers or
delivery systems
Carrier substrate or delivery system Authors
1. -Tricalcium phosphate
2. Autogenic cancellous bone graft combined with an onlay of purified
bone morphogenetic protein/non-collagenous proteins
3. Purified bone morphogenetic protein/non-collagenous proteins
suspended in a strip (1 X 13 cm) of polylactic/polyglycolic acid
copolymer or in gelation capsules
4. Bone matrix non-collagenous proteins
5. Porous hydroxyapatite combined with collagen
6. Composite of bone morphogenetic protein and plaster of paris
7. Demineralized bone matrix and bone morphogenetic protein in clot of
blood
8. Telopeptide-depleted bovine skin collagen
9. Polylactic acid homopolymers
10. Porous hydroxyapatite (replicas) obtained after hydrothermal conversion
of calcium carbonate exoskeleton of corals
11. Type I collagen
12. Porous hydroxyapatite blocks in form of discs (7 mm Φ, 3 mm thick) or
granules (400-620 μηι Φ)
13. Millipore diffusion chambers
14. Polylactic acid-polyethylene glycol block copolymer
15. Spongy titanium formed into a rice-shaped particle (2 mm3)
16. Natural coral skeleton in granules + flbrinogen glue
17. Porous biodegradable copolymer, poly(£>,£»C(lactide-coglycide))
particles (diameter 100-700 μηι)
18. Poly α-hydroxyacids as delivery vehicle
19. Fibrous glass membrane (fiber 1 μηι, thickness 0.6 mm) or porous
particles of hydroxyapatite
20. Granulated hydroxyapatite and fibrin
21. Chilin complex (artificial skin, absorbable thread)
22. Fibrous collagen membrane No. 3 from telopeptide,depleted bovine skin
collagen
23. Microcapsules made as mixture of polyZ),Z,-lactide-co-glycoIide and
polyethylene glycol methyl ether
Urist MR etui 1984(61)
Johnson EE9 Urist MR et al. 1988 (51)
Johnson EE, Urist MR et al. 1988 (52)
Kawamura M, Urist MR et al. 1988 (62)
Takaoka K et al. 1988 (63)
Yamazaki Υ et &L 1988(64)
Toriumi DM et al. 1991 (79)
Takaoka K, Kozeuka M, Nakahara H 1991 (65)
Miyamoto S et al. 1992 (66)
Ripamonti U, Ma S, Reddi AH 1992 (67)
Fujimari Fetal. 1992(68)
Ripamonti U, Ma S, Reddi AH 1992 (67)
Miyamoto S9 Takaoka K9 Ono K 1993 (69)
Miyamoto S et al. 1993 (70)
KawaiTetal 1993 (71)
ArnoudE, Vernejoul MC 1994 (72)
Muschler GF et al. 1994 (57)
Hollinger J 1994 (73)
KubokiYtt&L 1994(74)
Sato T 1994 (75)
Miyazava K et al. 1994 (76)
Kawanami M et al. 1994 (77)
h be A/etal. 1994(78)
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stituted with 3.13, 6.25, 12.5, 25.0, 50.0, 100, 200, 300
or 400 μg of recombinant human osteogenic protein-1.
All implants, except for those containing only 3.13 μg of
substance, induced complete radiographic osseus union
within eight weeks. Histological evaluation of this new
bone revealed primarily lamellar bone, with the forma-
tion of new cortices and normal-appearing marrow ele-
ments. Moreover, a single local application of recombi-
nant human osteogenic protein-1 on a carrier material
can completely restore large orthopaedic defects (55).
The possibility of using bone morphogenetic proteins in
spinal fusion has been carefully explored. The efficacy
of recombinant human bone morphogenetic protein-2
delivered in a porous biodegradable copolymer, poly-
(Z),Z,-lactide-coglycide) was evaluated using a canine
posterior segmental spinal fusion model (56, 57). Union
score and mechanical testing showed no difference be-
tween autogenous cancellous bone and recombinant hu-
man bone morphogenetic protein-2. These findings sug-
gest that synthetic bone graft substitutes delivering re-
combinant human bone morphogenetic protein-2 may be
suitable for posterior spinal fusions. The results obtained
on a similar model by Cook et al. (58) indicated that
recombinant human osteogenic protein-1 is an effective
bone graft substitute for achieving stable posterior spinal
fusion in a significantly more rapid fashion than can be
achieved with autogenous bone graft. The results re-
ported by Boden (59) and those of Sandhy et al. (60)
confirmed that bone morphogenetic proteins may serve
as powerful bone graft substitutes for lumbar spine fu-
sion.
The possibility of using bone morphogenetic protein for
the enhancement of osseous growth during implantation
of cementless endoprothesis of hip and knee joints has
also been the subject of preliminary clinical investiga-
tions. Bone morphogenetic proteins have proven both
their osteoinductive and osteoconductive potentials as
well as exceptional tolerance and immunological inert-
ness. At present, clinical trials on human patients are
being conducted. At this point in time, the greatest pro-
blem is the unresolved question of the carrier substance
and delivery system.
The carrier for bone morphogenetic proteins
Carrier substrates will have to meet the following
requirements:
1) relative insolubility in physiological conditions;
2) biodegradability;
3) protection against proteolytic activities;
4) function as substrate for cell adhesion and prolifera-
tion;
5) be immunologically inert;
6) achieve a slow release of a bone morphogenetic pro-
tein through controlled biological degradation, and
7) have mechanical stability in rebridging bony defects.
Some of these qualities are in part fulfilled by the vari-
ous organic and inorganic materials which have been
used as bone morphogenetic protein carriers (tab. 4) but
this problem has not yet been completely solved by any
research group. The fulfilment of the ideal properties of
an osteoinductive material, based on synthetic or natural
carrier, is a promising challenge for biomaterial re-
search.
Definitive evaluation of the clinical use of bone mor-
phogenetic protein will be possible after all the different
factors influencing implant activity have been eluci-
dated, and after development of an appropriate carrier.
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